11/6/2026

speaker
Conference Operator
Operator

Good day and thank you for standing by. Welcome to Humana's third quarter 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Lisa Stoner, Vice President of Investor Relations. Please go ahead.

speaker
Lisa Stoner
Vice President, Investor Relations, Humana

Thank you and good morning. We will begin this morning with brief remarks from Jim Rechtin, Humana's President and Chief Executive Officer, and Chief Financial Officer, Celeste Mellet. Following these remarks, we will host a question and answer session with industry analysts. Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our third quarter 2026 earnings press release as they relate to forward-looking statements along with other risks discussed in our SEC filing. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. Today's press release and posted remarks, our historical financial news releases, and our filings with the SEC are also available on our investor relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Any reference to earnings per share or EPS made during this conference call refer to diluted earnings per common share. Finally, this call is being recorded for replay purposes. That replay will be available on the investor relations page of Humana's website, Humana.com, later today. With that, I'll turn it over to Jim.

speaker
Jim Rechtin
President and Chief Executive Officer, Humana

Thank you, Lisa. Good morning, everyone, and thank you for joining us. We have just one headline today, and that is that we are in a good place. Execution is strong and improving. Signs point to our strategy working. We are increasingly seeing the tangible results of our team's good work. The results are positive for our members, our patients, and their health, and the results are contributing to our margin and earnings growth recovery, which is moving from on plan towards being ahead of plan. As usual, I will frame my comments today around the four drivers of our business. One, product and experience, which drive customer retention and growth. Two, clinical excellence, which delivers clinical outcomes and medical margin. Three, highly efficient operations. And four, capital allocation and growth in both CenterWell and Medicaid. Let's start with product and experience. Our 2026 membership, both new and returning, is performing in line to better than expected. Our 2027 product positioning also appears to be in line with expectations. Our product portfolio positions us largely as we expected at the time of bids. We believe our portfolio will deliver the margin progression in 2027 that is necessary to put us on track for a 3% plus margin in 2028. And importantly, our portfolio is focused on providing our members simple, affordable, and predictable coverage. It does this by protecting the benefits and services that seniors consistently identify as most important. So far, AEP performance is ahead of our initial expectations. Our recapture or retention of our members impacted by plan exits has been particularly strong, but we are also seeing new sales ahead of plan. And while it remains very early in AEP, we currently anticipate that our membership will be up for 2027. Turning to clinical excellence, I'm just going to say again that we are thrilled with our bonus year 28 or BY28 results. Our star ratings approach the highest ratings Humana has ever achieved with a member weighted star rating of 4.17. I'm proud of this team. This is truly the result of 65,000 associates working together to drive better experiences and health outcomes for our members. I'm going to provide just a few examples to bring this to life. Compared with the prior year, 663,000 more care opportunities were met. 534,000 additional members completed an annual preventative visit. 28,000 members received an overdue mammogram. This allowed us to identify 600 previously undetected breast cancers, many at an earlier stage than they otherwise would have been found. 93,000 members completed an overdue colorectal cancer screening. This allowed us to identify 100 previously undetected cases of pre-cancers and cancers. And 73,000 members living with diabetes received an overdue eye exam. This allowed us to identify 17,000 previously undetected diagnoses of diabetes-related eye disease, which is a leading cause of vision loss. Detecting these conditions early is critical to successfully treating them and managing the conditions. The improvement that the team has driven in the STARS program over the last two years is truly remarkable and is driving a real difference for our members. From a financial perspective, as we shared in the 8K and audio file in October, our BY28 results significantly exceed our goal of top quartile. As a reminder, results at roughly top quartile is the level of STARS performance that we believe is necessary to sustain a 3% margin and have competitive product. At or near top quartile performance is what is sustainable on an ongoing basis. We will have years close to top quartile, we will have years slightly above top quartile and we will have years like this year well above top quartile. However, we will manage the business assuming a level that approximates top quartile. That means our benefit structure and our broader cost structure must be tuned to and work closer to top quartile results, not at top decile. As a result, we anticipate a one-time tailwind in 2028. We expect to utilize some of this tailwind for one-time investments. These investments will help solidify our STARS capability and accelerate our efforts to improve the customer experience and improve clinical outcomes. We also expect additional one-time return to shareholders. We do not believe we can productively invest the full tailwind, and thus we will pass some through to shareholders. Once we have more information on 2028, which includes competitive dynamics, membership and product dynamics, and regulatory environment, we will quantify the level of and the expected use of the tailwind. will size how much we will invest and we will explain roughly how much will pass through to earnings. Now turning to BY29 stars, we continue to drive strong operational performance running roughly 5% ahead of last year's quality improvement rate on a per member basis in key HEDIS metrics at the end of Q3. We feel confident that we will achieve our goal of top quartile performance for BY29. Regarding highly efficient operations, our multi-year transformation is progressing as anticipated and we look forward to providing a more detailed update on this work at a December investor event. Finally, let me turn to capital allocation. I'll start with Medicaid, where we have implemented contracts in six new states over the last three years. With our Medicaid footprint now spanning 13 states, including 11 active states, and contracts awarded with implementations pending, in Georgia and Texas. Our Medicaid membership has grown by 104,000 members in 2026, largely driven by the start of the Michigan Heidi SNIP and the statewide Illinois FIDE SNIP programs, as well as the carbon of dual eligibles in the South Carolina Medicaid program. We are excited about these integrated dual programs, and we believe we are uniquely capable of delivering great outcomes for members and for states. within CenterWell Primary Care, we have driven strong growth this year, adding nearly 147,000 members or 30% growth, including the acquisition of MaxHealth in the first quarter. And we recently established a new partnership with BlackRock, which we are very excited about. Celeste will touch on this more in a moment. In conclusion, we are driving strong execution across the company, which has us on a positive trajectory. We are pleased with our 2026 performance to date and our increased full year outlook. We are incredibly proud of our BY28 STARS results and expect to maintain top quartile results for BY29. We are positioned as we expected for the 2027 AEP and we expect to make meaningful progress on MA margin expansion next year. And finally, we remain on track to deliver on our investor day commitments in 2028. which we will mark to market for you at the investor update on December 10th. With that, I will turn it to Celeste for a few remarks before Q&A.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API